MARKET

CASI

CASI

Casi Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6200
+0.1536
+32.93%
Opening 10:58 05/26 EDT
OPEN
0.4900
PREV CLOSE
0.4664
HIGH
0.6848
LOW
0.4670
VOLUME
988.30K
TURNOVER
377.08K
52 WEEK HIGH
1.775
52 WEEK LOW
0.3101
MARKET CAP
84.36M
P/E (TTM)
-2.7531
1D
5D
1M
3M
1Y
5Y
BRIEF-Casi Pharmaceuticals Inc - On May 23, Terminated Original License Agreement Dated Sept 17, 2014 Between Spectrum Pharmaceuticals Cayman, Lp, Co
reuters.com · 17h ago
A CASI Pharmaceuticals, Inc. (NASDAQ:CASI) insider increased their holdings by 10% last year
Viewing insider transactions for CASI Pharmaceuticals, Inc.'s ( NASDAQ:CASI ) over the last year, we see that insiders...
Simply Wall St. · 1d ago
Casi Pharmaceuticals stock rises on license/equity stake deal with China's Tianshi
Casi Pharmaceuticals (NASDAQ:CASI) is granting Beijing Tianshi Tongda Pharmaceuticals Technology an exclusive, perpetual, worldwide license for CID-103 for autoimmune diseases. Under the sublicense agreement, Casi will maintain the exclusive commercializat...
Seekingalpha · 2d ago
BRIEF-Casi Pharmaceuticals Enters Into Sublicense Agreement With Tianshi Pharmaceuticals For Anti-Cd38 Monoclonal Antibody Cid-103 In Autoimmune Field
reuters.com · 2d ago
CASI Pharmaceuticals Enters Sublicense Agreement With Beijing Tianshi Tongda Pharmaceuticals CASI To Receive Upfront Payment Of $10M In Two Instalments, Will Hold 15% Equity Of Tianshi Through Subsidiary
  ~ CASI to receive upfront payment of $10 million in two instalments ~ ~ CASI through its wholly-owned PRC subsidiary, will hold 15% equity of TIANSHI ~ ROCKVILLE, Md. and BEIJING, May 24, 2022
Benzinga · 2d ago
CASI PHARMACEUTICALS ENTERES INTO SUBLICENSE AGREEMENT WITH TIANSHI PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY (MAB) CID-103 IN AUTOIMMUNE FIELD
CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the signing of a Sublicense Agreement with Beijing Tianshi Tongda Pha...
PR Newswire · 2d ago
CASI Pharmaceuticals, Beijing Tianshi Tongda Sign Sublicense Deal for Autoimmune Disease Drug Candidate
MT Newswires · 2d ago
41 Stocks Moving In Monday's Mid-Day Session
Gainers Data Storage Corporation (NASDAQ: DTST) shares jumped 51.1% to $3.4750 after the company reported better-than-expected Q1 financial results.
Benzinga · 05/16 16:10
More
No Data
Learn about the latest financial forecast of CASI. Analyze the recent business situations of Casi Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

66.67%Strong Buy
33.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CASI stock price target is 4.500 with a high estimate of 6.00 and a low estimate of 3.000.
High6.00
Average4.500
Low3.000
Current 0.6270
EPS
Actual
Estimate
-0.07-0.05-0.04-0.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 66
Institutional Holdings: 32.12M
% Owned: 23.61%
Shares Outstanding: 136.06M
TypeInstitutionsShares
Increased
7
599.31K
New
5
129.81K
Decreased
14
2.78M
Sold Out
10
2.58M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.67%
Pharmaceuticals & Medical Research
+0.75%
Key Executives
Chairman/Chief Executive Officer/Director
Wei-Wu He
President
Wei Zhang
Executive Vice President
Alexander Zukiwski
Independent Director
James Huang
Independent Director
Franklin Salisbury
Independent Director
Rajesh Shrotriya
Independent Director
Y. Alexander Wu
Independent Director
Quan Zhou
No Data
No Data
About CASI
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company’s operations in China are conducted primarily through its subsidiaries, which includes CASI Pharmaceuticals (China) Co., Ltd. (CASI China), which is wholly owned and is located in Beijing, China, and CASI Pharmaceuticals (Wuxi) Co., Ltd. (CASI Wuxi), which is located in Wuxi, China. Its commercial product, EVOMELA, is developed for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The Company’s other core hematology/oncology assets in its pipeline include: CNCT19, BI-1206, CB-5339 and CID-103.

Webull offers kinds of CASI Pharmaceuticals Inc stock information, including NASDAQ:CASI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CASI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CASI stock methods without spending real money on the virtual paper trading platform.